Non-replicative antibiotic resistance-free DNA vaccine encoding S and N proteins induces full protection in mice against SARS-CoV-2

Front Immunol. 2022 Nov 9:13:1023255. doi: 10.3389/fimmu.2022.1023255. eCollection 2022.

Abstract

SARS-CoV-2 vaccines currently in use have contributed to controlling the COVID-19 pandemic. Notwithstanding, the high mutation rate, fundamentally in the spike glycoprotein (S), is causing the emergence of new variants. Solely utilizing this antigen is a drawback that may reduce the efficacy of these vaccines. Herein we present a DNA vaccine candidate that contains the genes encoding the S and the nucleocapsid (N) proteins implemented into the non-replicative mammalian expression plasmid vector, pPAL. This plasmid lacks antibiotic resistance genes and contains an alternative selectable marker for production. The S gene sequence was modified to avoid furin cleavage (Sfs). Potent humoral and cellular immune responses were observed in C57BL/6J mice vaccinated with pPAL-Sfs + pPAL-N following a prime/boost regimen by the intramuscular route applying in vivo electroporation. The immunogen fully protected K18-hACE2 mice against a lethal dose (105 PFU) of SARS-CoV-2. Viral replication was completely controlled in the lungs, brain, and heart of vaccinated mice. Therefore, pPAL-Sfs + pPAL-N is a promising DNA vaccine candidate for protection from COVID-19.

Keywords: DNA vaccine; N protein; S protein; SARS-CoV-2; furin; mouse model; pPAL.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents
  • COVID-19 Vaccines
  • COVID-19* / prevention & control
  • Humans
  • Mammals
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Pandemics
  • SARS-CoV-2
  • Vaccines, DNA*
  • Viral Vaccines*

Substances

  • Vaccines, DNA
  • Viral Vaccines
  • COVID-19 Vaccines
  • Anti-Bacterial Agents